Dr. Juan Granada, New President and CEO of the Cardiovascular Research Foundation

The prestigious Colombian Interventional Cardiologist was appointed President and Chief Executive Officer (CEO) of the Cardiovascular Research Foundation (CRF) 15 days ago. He is now also a member of the CRF board of Directors.

Dr. Juan Granada, New President and CEO of the Cardiovascular Research Foundation

SOLACI wishes Dr. Granada congratulations for this well deserved recognition and wishes him the best for the important challenge ahead. We are sure his experience and leadership will promote CRF sustained growth, to consolidate as one of the world’s referents in terms of interventional cardiology.

 

We also take this opportunity to thank the unconditional support and tireless collaboration of Dr. Granada towards SOLACI all these years. We hope to strengthen the ties between both organizations, to generate new initiatives and joint actions to keep fostering the development of interventional cardiology in Latin America and the rest of the world.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Check out the best images of the El Salvador 2024 Sessions

Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Virtual Event SOLACI-Medtronic | The Visible Heart Lab

We invite you to participate in a new virtual activity organized in collaboration with Medtronic, focused on "The Visible Heart Lab" and dedicated to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....